drugset
drugset / Trial / NCT00093470

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00093470 ↗

Phase 3 Completed 144 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase III trial studies tipifarnib in treating patients with acute myeloid leukemia (AML) in remission. Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether tipifarnib is more effective than observation alone in preventing the recurrence of AML.

Timeline

Start
2004-08-18
Primary completion
2015-02-20
Completion
2015-04-14

Drugs

EvaluationDrugModalityDoseRoute
Subject tipifarnib Small molecule — Oral

Indications

acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent acute myeloid leukemia with minimal differentiation acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute myeloid leukemia, t(8;21)(q22; q22.1) acute myeloid leukemia, t(9;11)(p21.3;q23.3) acute myelomonocytic leukemia M4 adult acute monocytic leukemia erythroleukemia myelodysplastic syndrome with excess blasts